Di Stefano B, Ueda M, Sabri S, et al. Reduced MEK inhibition preserves genomic stability in naive human embryonic stem cells. Nat Methods. 2018;15(9):732-740. doi:10.1038/s41592-018-0104-1
Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends Cell Biol. 2018;28(11):911-925. doi:10.1016/j.tcb.2018.07.002
Wagner FF, Bishop JA, Gale JP, et al. Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. ACS Chem Biol. 2016;11(7):1952-63. doi:10.1021/acschembio.6b00306
Pikman Y, Stegmaier K. Targeted therapy for fusion-driven high-risk acute leukemia. Blood. 2018;132(12):1241-1247. doi:10.1182/blood-2018-04-784157
Sundberg TB, Choi HG, Song JH, et al. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proc Natl Acad Sci U S A. 2014;111(34):12468-73. doi:10.1073/pnas.1412308111
Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471-475. doi:10.1038/nature23465
Luo T, Masson K, Jaffe JD, et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A. 2012;109(8):2860-5. doi:10.1073/pnas.1120589109
Hua Z, Huang X, Bregman H, et al. 2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors. Bioorg Med Chem Lett. 2012;22(17):5392-5. doi:10.1016/j.bmcl.2012.07.046
Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature. 1995;377(6548):441-6. doi:10.1038/377441a0
Hinze L, Pfirrmann M, Karim S, et al. Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. Cancer Cell. 2019;35(4):664-676.e7. doi:10.1016/j.ccell.2019.03.004